361 related articles for article (PubMed ID: 24407233)
1. Body weight, gender and response to TNF-α blockers in axial spondyloarthritis.
Gremese E; Bernardi S; Bonazza S; Nowik M; Peluso G; Massara A; Tolusso B; Messuti L; Miceli MC; Zoli A; Trotta F; Govoni M; Ferraccioli G
Rheumatology (Oxford); 2014 May; 53(5):875-81. PubMed ID: 24407233
[TBL] [Abstract][Full Text] [Related]
2. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study.
Spadaro A; Punzi L; Marchesoni A; Lubrano E; Mathieu A; Cantini F; Olivieri I; Salvarani C; Scarpa R; Scrivo R; Ramonda R; Porru G; D'Angelo S; Catanoso M; Atteno M; Valesini G
Rheumatology (Oxford); 2010 Jun; 49(6):1107-11. PubMed ID: 20223813
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
4. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis.
Villiger PM; Caliezi G; Cottin V; Förger F; Senn A; Østensen M
Ann Rheum Dis; 2010 Oct; 69(10):1842-4. PubMed ID: 20610443
[TBL] [Abstract][Full Text] [Related]
5. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?
Bhalme M; Sharma A; Keld R; Willert R; Campbell S
Eur J Gastroenterol Hepatol; 2013 May; 25(5):543-9. PubMed ID: 23337170
[TBL] [Abstract][Full Text] [Related]
6. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study.
Spadaro A; Lubrano E; Marchesoni A; D'Angelo S; Ramonda R; Addimanda O; Perrotta FM; Olivieri I; Punzi L; Salvarani C
Rheumatology (Oxford); 2013 Oct; 52(10):1914-9. PubMed ID: 23878312
[TBL] [Abstract][Full Text] [Related]
7. Increase in bone density in patients with spondyloarthritis during anti-tumor necrosis factor therapy: 6-year followup study.
Durnez A; Paternotte S; Fechtenbaum J; Landewé RB; Dougados M; Roux C; Briot K
J Rheumatol; 2013 Oct; 40(10):1712-8. PubMed ID: 23950191
[TBL] [Abstract][Full Text] [Related]
8. Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study.
Lubrano E; Perrotta FM; Marchesoni A; D'Angelo S; Ramonda R; Addimanda O; Olivieri I; Punzi L; Salvarani C
J Rheumatol; 2015 Feb; 42(2):258-63. PubMed ID: 25512483
[TBL] [Abstract][Full Text] [Related]
9. Biological drug treatment of rheumatoid arthritis and spondyloarthritis: effects on QT interval and QT dispersion.
DI Franco M; Paradiso M; Ceccarelli F; Scrivo R; Spinelli FR; Iannuccelli C; Valesini G
J Rheumatol; 2012 Jan; 39(1):41-5. PubMed ID: 22045840
[TBL] [Abstract][Full Text] [Related]
10. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.
Maksymowych WP; Inman RD; Gladman D; Thomson G; Stone M; Karsh J; Russell AS;
J Rheumatol; 2003 Jun; 30(6):1356-63. PubMed ID: 12784417
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
Gisondi P; Cotena C; Tessari G; Girolomoni G
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
[TBL] [Abstract][Full Text] [Related]
12. Efficacy in current practice of switching between anti-tumour necrosis factor- α agents in spondyloarthropathies.
Paccou J; Solau-Gervais E; Houvenagel E; Salleron J; Luraschi H; Philippe P; Duquesnoy B; Flipo RM
Rheumatology (Oxford); 2011 Apr; 50(4):714-20. PubMed ID: 21131271
[TBL] [Abstract][Full Text] [Related]
13. Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy.
Iannone F; Fanizzi R; Scioscia C; Anelli MG; Lapadula G
Scand J Rheumatol; 2013; 42(1):41-4. PubMed ID: 22991950
[TBL] [Abstract][Full Text] [Related]
14. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment.
Briot K; Gossec L; Kolta S; Dougados M; Roux C
J Rheumatol; 2008 May; 35(5):855-61. PubMed ID: 18381782
[TBL] [Abstract][Full Text] [Related]
15. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of tumor necrosis factor α blockers in early axial spondyloarthritis: data from the DESIR cohort.
Moltó A; Paternotte S; Claudepierre P; Breban M; Dougados M
Arthritis Rheumatol; 2014 Jul; 66(7):1734-44. PubMed ID: 24623678
[TBL] [Abstract][Full Text] [Related]
17. Early increase of abdominal adiposity in patients with spondyloarthritis receiving anti-tumor necrosis factor-α treatment.
Hmamouchi I; Roux C; Paternotte S; Kolta S; Dougados M; Briot K
J Rheumatol; 2014 Jun; 41(6):1112-7. PubMed ID: 24737911
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Callhoff J; Sieper J; Weiß A; Zink A; Listing J
Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
[TBL] [Abstract][Full Text] [Related]
19. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.
Micheroli R; Hebeisen M; Wildi LM; Exer P; Tamborrini G; Bernhard J; Möller B; Zufferey P; Nissen MJ; Scherer A; Ciurea A;
Arthritis Res Ther; 2017 Jul; 19(1):164. PubMed ID: 28724442
[TBL] [Abstract][Full Text] [Related]
20. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
